Search

Your search keyword '"E. Catherinot"' showing total 2 results
Start Over Author "E. Catherinot" Publisher biomed central ltd
2 results on '"E. Catherinot"'

1. Tezepelumab for refractory eosinophilic granulomatosis with polyangiitis-related asthma.

Author

Vincent-Galtié N, Marquant Q, Catherinot E, Ackermann F, Magnan A, Tcherakian C, and Groh M

Subjects
Humans, Middle Aged, Female, Male, Treatment Outcome, Anti-Asthmatic Agents therapeutic use, Churg-Strauss Syndrome drug therapy, Churg-Strauss Syndrome diagnosis, Granulomatosis with Polyangiitis drug therapy, Granulomatosis with Polyangiitis diagnosis, Asthma drug therapy, Asthma diagnosis, Antibodies, Monoclonal, Humanized therapeutic use
Abstract

Conventional immunosuppressants are ineffective for the management of EGPA-related asthma. Tezepelumab is a human monoclonal antibody that inhibits thymic stromal lymphopoietin (TLSP) that has proven efficacy in several phase 3 studies for the treatment of asthma. We treated with off-label tezepelumab the first two patients with severe refractory EPGA-related asthma. These preliminary findings suggest that targeting upstream signaling of the T2 inflammatory pathway can improve symptoms, reduce BVAS and increase Asthma Control Test scores, even in patients with refractory asthma who have failed several previous lines of treatment. Nevertheless, by analogy with dupilumab-induced IL-4/13 blockade, the persistence of sputum eosinophilia (reported in both patients) raises questions as to whether TSLP inhibition could lead to a rebound of eosinophilia and potentially to eosinophil-related symptoms in patients with EGPA., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

2. Primary immunodeficiency-related bronchiectasis in adults: comparison with bronchiectasis of other etiologies in a French reference center.

Author

Goussault H, Salvator H, Catherinot E, Chabi ML, Tcherakian C, Chabrol A, Didier M, Rivaud E, Fischer A, Suarez F, Hermine O, Lanternier F, Lortholary O, Mahlaoui N, Devillier P, and Couderc LJ

Subjects
Adult, Age Factors, Cohort Studies, Comorbidity, Cystic Fibrosis, Female, France epidemiology, Humans, Male, Middle Aged, Prevalence, Prognosis, Respiratory Function Tests, Retrospective Studies, Risk Assessment, Severity of Illness Index, Sex Factors, Survival Analysis, Tertiary Care Centers, Bronchiectasis diagnosis, Bronchiectasis epidemiology, Cause of Death, Primary Immunodeficiency Diseases diagnosis, Primary Immunodeficiency Diseases epidemiology
Abstract

Background: Bronchiectasis is a heterogeneous disease depending on etiology. It represents the most frequent non-infectious pulmonary complication of primary immunodeficiencies (PID). We investigated whether bronchiectasis associated with PID had a distinct course in comparison to bronchiectasis of other causes., Methods: Retrospective single-center study of adult patients diagnosed with non-cystic fibrosis bronchiectasis with more than 5 years of follow-up and at least 4 pulmonary functional tests available at one year apart. They were divided into three groups: PID- related bronchiectasis, idiopathic/post infectious-related bronchiectasis and other causes of bronchiectasis. Respiratory functional data and clinical outcomes were compared., Results: Of 329 patients with bronchiectasis diagnosed in Foch Hospital (Suresnes, France), 98 patients fulfilled the selected criteria (20 PID-related cases, 39 idiopathic or post-infectious cases, and 39 cases with other causes). Median time of follow-up was 9.5 years. Groups were similar concerning initial characteristics (female 70.4%, never smokers 59.2%, mild severity bronchiectasis according to the FACED score and median FEV1 at diagnosis 73.5% predicted values [Q1-Q3: 53.75-90.5]), except PID patients who were younger (median age of 51.5 vs 62 years, p = 0.02). Eighty-five percent of PID patients received immunoglobulin substitution (median trough level was measured at 10.5 g/dl [10;10.92]). Global median FEV1 annual decline was 25.03 ml/year [8.16;43.9] and 19.82 ml/year [16.08;48.02] in the PID patients group. Forty-five percent of patients had bacterial colonization, pneumoniae occurred in 56% of patients and median exacerbation annual rate was 0.8 [0.3-1.4]. Hemoptysis occurred in 31.6% of patients. Global mortality rate was 11.2%. We did not record any significant difference for all clinical and functional outcomes between patients with PID and other etiologies. The median decline in FEV1 was similar in the three groups., Conclusions: The course of PID-related bronchiectasis was similar to bronchiectasis of other causes. Provided that patients receive immunoglobulin replacement, the course of PID-related bronchiectasis seems to be independent of the underlying immune disorder.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results